LivaNova (NASDAQ:LIVN) Shares Cross Below Fifty Day Moving Average - Time to Sell?

Key Points

• LivaNova shares fell below their 50-day moving average, trading as low as $74.64 versus the $79.30 average, signaling recent technical weakness.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $84.12; six analysts rate the stock a Buy and five rate it a Hold.
• The company recently exceeded quarterly expectations, reporting $1.26 in EPS and $390.59 million in revenue, while revenue increased 10.8% year over year. However, insiders sold 7,450 shares worth about $591,839 during the last quarter.

LivaNova PLC (NASDAQ:LIVN - Get Free Report)'s share price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $79.30 and traded as low as $74.64. LivaNova shares last traded at $75.07, with a volume of 528,515 shares changing hands.

Analysts Set New Price Targets

A number of analysts recently issued reports on LIVN shares. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research note on Wednesday, August 5th. Needham & Company LLC upped their price target on shares of LivaNova from $81.00 to $93.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Freedom Capital upgraded shares of LivaNova to a "hold" rating in a research note on Tuesday, June 30th. Zacks Research lowered LivaNova from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Finally, Piper Sandler reiterated an "overweight" rating and set a $90.00 target price (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, LivaNova has an average rating of "Moderate Buy" and a consensus price target of $84.12.

LivaNova Price Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The firm has a market cap of $4.14 billion, a price-to-earnings ratio of 22.21 and a beta of 0.87. The stock's fifty day moving average price is $79.30 and its 200-day moving average price is $74.54.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same period in the previous year, the business earned $1.05 EPS. The company's revenue was up 10.8% on a year-over-year basis. Equities research analysts predict that LivaNova PLC will post 3.78 EPS for the current fiscal year.

Insider Activity at LivaNova

In other news, Director Brooke Story sold 2,300 shares of the company's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company's stock, valued at approximately $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company's stock, valued at approximately $345,896.34. The trade was a 44.11% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 7,450 shares of company stock worth $591,839. Company insiders own 0.35% of the company's stock.

Institutional Investors Weigh In On LivaNova

Several large investors have recently made changes to their positions in LIVN. Allworth Financial LP lifted its stake in LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company's stock worth $25,000 after purchasing an additional 144 shares during the period. State of Michigan Retirement System grew its stake in shares of LivaNova by 1.5% in the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company's stock valued at $833,000 after purchasing an additional 200 shares during the period. Hantz Financial Services Inc. grew its position in LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock valued at $27,000 after acquiring an additional 267 shares during the period. GAMMA Investing LLC grew its holdings in shares of LivaNova by 18.2% in the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company's stock worth $151,000 after purchasing an additional 283 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of LivaNova by 2.7% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,250 shares of the company's stock worth $715,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company's principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.